Renji Hospital

This early-phase trial tests a new cell therapy called BEN301 for several autoimmune diseases, including scleroderma and rheumatoid arthritis. The therapy uses specially engineered immune cells (CAR-Treg cells) to calm the overactive immune system. The study involves 24 adults an…

This study tests a combination of two drugs, cadonilimab and lenvatinib, in 28 adults with advanced clear cell kidney cancer that worsened after initial immunotherapy. The goal is to see if the combo can shrink tumors or slow disease progression. Participants receive treatment un…

This study tests a combination of two drugs (fruquintinib and serplulimab) as the first treatment for people with a rare type of kidney cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors or slow the disease. About 39 adults will t…

This early trial tests whether combining the drug lenvatinib with a new experimental drug, VIC-1911, is safe and can shrink tumors in people with advanced liver cancer. Only 12 participants will be enrolled, and the study is open-label, meaning everyone gets the combination. The …

This study looks at how well minimally invasive procedures (like balloons and stents) work for people with severe blockages in the leg arteries. It will track 1000 patients to see if these treatments restore blood flow and keep arteries open over time. The goal is to find the bes…

This study compares two types of brain surgery for people with a severe head injury that causes a blood clot (epidural hematoma) and brain herniation. One surgery removes the clot and a piece of skull to relieve pressure; the other removes the clot without removing skull bone. Th…

This early-phase study is testing a single dose of a new drug called YOLT-202 in 18 adults with Alpha-1 antitrypsin deficiency (AATD), a genetic condition that can damage the lungs and liver. The main goal is to see if the drug is safe and to find the best dose. Participants will…

This phase 2 trial is testing whether adding the targeted drug pyrotinib to standard chemotherapy and trastuzumab before surgery can eliminate more cancer in women with HER2-positive early breast cancer. About 53 participants will receive the combination, and the main goal is to …

This study aims to create computer models that predict how long patients with advanced pancreatic cancer might live and how well they respond to chemotherapy. Researchers will use medical images, tissue samples, and genetic data from 100 patients. The goal is to help doctors make…